EGFR and neoplasm: Monoclonal antibodies exert their inhibitory effects on tumor cell proliferation by binding to the extracellular ligand-binding region of EGFR, thereby preventing its binding to endogenous ligands and consequently inhibiting the EGFR signaling pathway.